| 1 | Genetic engineering of megakaryocytes from blood progenitor cells using messenger RNA lipid nanoparticles. (Leung J, Primbetova A, Strong C, Hay BN, Hsu HH, Hagner A, Foster LJ, Devine D, Cullis PR, Zandstra PW, Kastrup CJ) J Thromb Haemost 2025 Jan;23(1):306-313 |
| 1 | Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices. (Strong C, Leung J, Kang E, Badior KE, Robertson M, Pereyra N, Rowe EM, Wietrzny A, Ma B, Noronha Z, Arnold D, Ciufolini MA, Devine DV, Jan E, Cullis PR, Kastrup CJ) Blood 2024 Nov 21;144(21):2223-2236 1 Citation |
| 1 | Emerging gene therapies for enhancing the hemostatic potential of platelets. (Leung J, Cau MF, Kastrup CJ) Transfusion 2021 Jul;61 Suppl 1:S275-S285 2 Citations |
| 1 | Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. (Ghoneim HE, Zamora AE, Thomas PG, Youngblood BA) Trends Mol Med 2016 Dec;22(12):1000-1011 59 Citations |
| 1 | Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. (Resetca D, Neschadim A, Medin JA) J Immunother 2016 Sep;39(7):249-59 8 Citations |
| 1 | Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. (Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T) Br J Haematol 2016 Mar;172(5):685-98 57 Citations |
| 1 | A Candida albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of Fungal Growth during Disseminated Infection. (Huppler AR, Whibley N, Woolford CA, Childs EE, He J, Biswas PS, McGeachy MJ, Mitchell AP, Gaffen SL) Infect Immun 2015 Sep;83(9):3684-92 5 Citations |
| 1 | Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. (Sato T, Neschadim A, Nakagawa R, Yanagisawa T, Medin JA) Methods Mol Biol 2015;1317:55-67 3 Citations |
| 1 | Lentiviral vectors in cancer immunotherapy. (Oldham RA, Berinstein EM, Medin JA) Immunotherapy 2015;7(3):271-84 29 Citations |
| 2 | Agrochemical control of plant water use using engineered abscisic acid receptors. (Park SY, Peterson FC, Mosquna A, Yao J, Volkman BF, Cutler SR) Nature 2015 Apr 23;520(7548):545-8 221 Citations |
| 3 | Targeted disruption of Tbc1d20 with zinc-finger nucleases causes cataracts and testicular abnormalities in mice. (Park AK, Liegel RP, Ronchetti A, Ebert AD, Geurts A, Sidjanin DJ) BMC Genet 2014 Dec 05;15:135 19 Citations |
| 2 | In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. (Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q) J Thromb Haemost 2014 Aug;12(8):1283-93 33 Citations |
| 1 | Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. (Wang JC, Felizardo TC, Au BC, Fowler DH, Dekaban GA, Medin JA) Virol J 2013 Jul 20;10:240 9 Citations |
| 1 | Krüppel-like Factor 7 engineered for transcriptional activation promotes axon regeneration in the adult corticospinal tract. (Blackmore MG, Wang Z, Lerch JK, Motti D, Zhang YP, Shields CB, Lee JK, Goldberg JL, Lemmon VP, Bixby JL) Proc Natl Acad Sci U S A 2012 May 08;109(19):7517-22 230 Citations |
| 1 | Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. (Neschadim A, Wang JC, Lavie A, Medin JA) Cancer Gene Ther 2012 May;19(5):320-7 20 Citations |
| 1 | Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. (Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA) Mol Ther 2012 May;20(5):1002-13 20 Citations |
| 2 | Control of intestinal Nod2-mediated peptidoglycan recognition by epithelium-associated lymphocytes. (Duerr CU, Salzman NH, Dupont A, Szabo A, Normark BH, Normark S, Locksley RM, Mellroth P, Hornef MW) Mucosal Immunol 2011 May;4(3):325-34 26 Citations |
| 1 | Unmasking different mechanical and energetic roles for the small heat shock proteins CryAB and HSPB2 using genetically modified mouse hearts. (Pinz I, Robbins J, Rajasekaran NS, Benjamin IJ, Ingwall JS) FASEB J 2008 Jan;22(1):84-92 38 Citations |
| 1 | Strategies for the use of site-specific recombinases in genome engineering. (Jones JR, Shelton KD, Magnuson MA) Methods Mol Med 2005;103:245-57 25 Citations |
| 1 | Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. (Zhu D, Qi CF, Morse HC 3rd, Janz S, Stevenson FK) Blood 2005 Mar 01;105(5):2135-7 34 Citations |
| 1 | Windows into development: historic, current, and future perspectives on transgenic zebrafish. (Udvadia AJ, Linney E) Dev Biol 2003 Apr 01;256(1):1-17 168 Citations |
| 1 | Use of transgenic and knockout strategies in mice. (Ryan MJ, Sigmund CD) Semin Nephrol 2002 Mar;22(2):154-60 3 Citations |
| 1 | Appropriate tissue- and cell-specific expression of a single copy human angiotensinogen transgene specifically targeted upstream of the HPRT locus by homologous recombination. (Cvetkovic B, Yang B, Williamson RA, Sigmund CD) J Biol Chem 2000 Jan 14;275(2):1073-8 43 Citations |
| 1 | Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. (Medin JA, Takenaka T, Carpentier S, Garcia V, Basile JP, Segui B, Andrieu-Abadie N, Auge N, Salvayre R, Levade T) Hum Gene Ther 1999 May 20;10(8):1321-9 33 Citations |
| 1 | Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. (Medin JA, Hunt L, Gathy K, Evans RK, Coleman MS) Proc Natl Acad Sci U S A 1990 Apr;87(7):2760-4 72 Citations |
| 1 | Antibiotic resistance mutations in ribosomal RNA genes of Escherichia coli. (Sigmund CD, Ettayebi M, Borden A, Morgan EA) Methods Enzymol 1988;164:673-90 174 Citations |
© 2025 Clinical & Translational Science Institute